GEXVal Increases Capital of Its Australian Subsidiary
December 1, 2021
GEXVal Inc. (President and CEO, Dr. Juran Kato; location, Kanagawa, Japan) has increased the capital of its wholly-owned subsidiary in Australia, GEXVal AU Pty Ltd.
GEXVal always considers patients and families first and committed to deliver novel therapeutic drugs with agility. GEXVal is currently under preparation to conduct the first clinical study through this Australian subsidiary.
Australia is well known for its policy to promote venture businesses in the life science field. Both the national and state governments offer various supportive initiatives for new businesses in this field. Early clinical development in Australia has three advantages: First, Australia has a system that promotes rapid and step-wise clinical development with significant flexibility. Second, In the field of neurodevelopmental disorders which GEXVal is focusing on, Australia has a track record on completing the early-stage clinical development, followed by quick and smooth transition to late-stage clinical development in the U.S. Third, start-up businesses like us can benefit from the scheme such as Australian R&D Tax Incentive.
Subsidiary in Australia
Name of the company: GEXVal AU Pty Ltd
Location: L 5 63 Pirie St, Adelaide, SA 5000, Australia
Establishment: June 23, 2021
Capital: AUD 50,000 (As of December 2, 2021)
Executive officer: Juran Suzuki
GEXVal is a Japan-based bioventure, tackling Access to Medicine issues for patients and families who live with rare and intractable diseases. GEXVal is fully committed to bringing hope and smile to those who are waiting for better treatment options.
For future information, please contact us: firstname.lastname@example.org